Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
4.990
+0.510 (11.38%)
Oct 8, 2025, 10:29 AM EDT - Market open
Dermata Therapeutics Employees
Dermata Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,291,097
Market Cap
3.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 1 | 14.29% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DRMA News
- 6 days ago - Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office - Accesswire
- 21 days ago - Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025 - Accesswire
- 22 days ago - Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th - GlobeNewsWire
- 4 weeks ago - Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments - Accesswire
- 7 weeks ago - Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Accesswire
- 3 months ago - Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis - Accesswire
- 5 months ago - Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Accesswire
- 6 months ago - Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - Accesswire